



Corporate
455 East 500 South
Suite 205
Salt Lake City, UT 84111

Lab
1266 South 1380 West
Orem, UT 84058

www.Nu-MedPlus.com

JULY 17, 2015

Dear Shareholder,

We would like to update you on your Company's status.

Nu-Med Plus, Inc. is in the process of preparing for increased trading of its' shares in the marketplace. To this end, your Company will be seeking market makers, retail backers and institutional investors, all aimed at ultimately increasing investor awareness and shareholder value. To assist us in this endeavor, we are proud to announce the selection of New York-based corporate advisory firms Affinity Advisors and NT Associates as our strategic public relations partners. These firms will be responsible for directing and executing a corporate plan for increased investor awareness and shareholder expansion of Nu-Med Plus. Please find enclosed related investment material which will be disseminated to potential investors. This material highlights the work being done at your Company, specifically with regard to its' inhaled Nitric Oxide products.

Additionally, we are pleased to announce that we have completed the development of a compressed, proprietary tablet formulation for our Inhaled Nitric Oxide Hospital System. The tablet formulation is important because of its ease of handling and efficiency. This system can be used by adults, pediatrics and neonates who are on a ventilator. We are also excited about 2 new products we are developing relating to our Inhaled Nitric Oxide platform. We will be releasing announcements shortly about these innovative products.

Nitric Oxide gas has been the subject of extensive international research, and has shown to be effective on numerous modalities. Due to worldwide outbreaks of MERS, SARS and the Bird Flu, Nu-Med Plus has received numerous inquiries and communications from international medical device companies and distributors regarding our products, while solutions to these deadly viruses are pursued. We believe it is important for our shareholders to understand that inhaled Nitric Oxide is FDA approved for specific therapies in the United States. It is equally important to know that there is growing public interest in your Company's ability to create medical devices that deliver cost-effective, inhaled Nitric Oxide to patients in a manner unique to the market.

NU-MED PLUS, Inc. remains dedicated in its' desire to increase shareholder value through the origination and advancement of new ideas and products, and by efficiently disseminating pertinent Corporate information to the investing public in a timely manner.

Feel free to contact me with any questions.

Best regards,

Jeffrey L. Robins/President
NU-MED PLUS, Inc.
PH: 801-746-3570 Email:jeff@nu-medplus.com

This shareholder letter and accompanying documents may contain forward-looking statements. Forward-looking statements are indicated by words such as "expects," "intends," "anticipates," "believes" and similar expressions. Our ability to achieve the results anticipated in such forward-looking statements is subject to risks and uncertainties, including, without limitation, our ability to successfully centralize and consolidate various support functions, in addition to general economic conditions, operating results, market acceptance of our solutions and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission. These forward-looking statements are made in accordance with "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and no assurance can be given that the future results that are the subject of such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.